Sinovac – pharmaceutical daily

July 6, 2020 Off

Sinovac COVID-19 vaccine collaboration with Butantan approved by Brazilian regulator for Phase III Trial

Sinovac Biotech’s partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines, has reached a milestone as it moved one step further to our commitment to developing vaccines for global use after getting the approval for Phase 3 trial from Brazilian National Regulatory Agency, Anvisa.

May 22, 2020 Off

Sinovac secures $15M for COVID-19 vaccine dvelopment

By BusinessWire

Advantech Capital and Vivo Capital have invested $15 million in Sinovac Research and Development Co., Ltd. (“Sinovac R&D”), a wholly owned subsidiary of Sinovac, to further the development of an inactivated vaccine against COVID-19 named CoronaVac.

April 30, 2019 Off

Sinovac second half 2018 sales remains same, 2018 annual report on Form 20-F

By BusinessWire

Revenuegenerated by Hepatitis A vaccine increased by $12.0 million comparedto same period in 2017, which was offset by $13.6 million decrease in